Group 3: histidine, lysine, arginine.
In some cases, the peptide therapeutic agent is histidine.
In the case of L-Histidine, the overloading of the L-system is avoided and a more constant concentration of L-Histidine can be provided in the gastrointestinal tract.
A controlled or sustained release of L-Histidine is provided by coating the L-Histidine with a hydrophobic coating or acid-resistant coating such as a glyceride material derived from rapeseed.
A therapeutic agent for cerebral ischemic injury contains at least one compound selected from L-alanyl-L-histidine and glycyl-L-histidine as an active ingredient.
The histidine residue is present at a position other than the N-terminus of the aforesaid polypeptide.
L-Histidine is preferably administered a s a single oral dose comprised from 0.2-20 g.
N-L-methionyl-387-L-histidine-388-L-alanine-1-388-toxin (Corynebacterium diphtheriae strain C7) (388?2')-protein (INNCN
histidine-249-L-methionine-250-L-alanine-251-L-glutamic acid-248-613-exotoxin A (Pseudomonas aeruginosa reduced) (INNCN
N-L-methionyl-387-L-histidine-388-L-alanine-1-388-toxin (Corynebacterium diphtheriae strain C7) (388→2′)-protein (INNCN
N-L-methionyl-387-L-histidine-388-L-alanine-1-388-toxin (Corynebacterium diphtheriae strain C7) (388→2')-protein (INNCN
It is intended to provide a process for producing L-histidine with the use of a bacterium belonging to the family Enterobacteriaceae the L-amino acid productivity of which has been enhanced by enhancing its transaldolase activity encoded by gene talB.
Amino acid cysteine, asparagine, glutamine, lysine, arginine, and/or histidine are particularly suitable for said type of modification.
To improve the stability of vaccines comprising aluminium salt(s), the invention uses the amino acid histidine.
The figure illustrates the phosphorylation of SpoOF including a histidine linker or tag ('His-SpoOF') by KinA.